Case Study: Humira Cost Savings Through Biosimilar Access

Client: Mid-size biotech conducting multiple clinical trials

Challenge: The client required a large quantity of Humira (adalimumab) for several upcoming studies. High costs and limited availability were putting pressure on study budgets and timelines.

Solution: CSI leveraged its industry insight and direct relationships with the manufacturer to provide access to a high-quality adalimumab biosimilar. This saved the client a staggering 50% on price. By carefully coordinating sourcing and supply, we ensured uninterrupted study timelines while maintaining compliance.

Results:

• Cost savings: Thousands of dollars saved with biosimilar adalimumab compared to brand-name Humira.

• Timely supply: No delays in trial enrolment or dosing schedules.

• Seamless support: Certificates of Analysis (CoAs), first-leg documents and stability data were provided.

Conclusion: By partnering with CSI, the client was able to reduce drug costs significantly without compromising on quality or timelines, demonstrating the value of strategic comparator sourcing for clinical trials. 

Book a consultation